There is limited information about the benefits of pulmonary rehabilitation (PR) in patients with bronchiectasis. This study aimed to evaluate the effects of an out-patient PR program in patients with a primary diagnosis of bronchiectasis and to compare them with a matched COPD group who completed the same PR program. A retrospective review was conducted of patients with bronchiectasis or COPD who completed 6 to 8 weeks of PR at two tertiary institutions. The outcome measures were the 6-minute walk distance (6MWD) and Chronic Respiratory Disease Questionnaire (CRQ). Ninety-five patients with bronchiectasis completed the PR (48 male; FEV 1 63 [24] % predicted; age 67 [10] years). Significant improvements in 6MWD (mean change 53.4 m, 95% CI 45.0 to 61.7) and CRQ total score (mean change 14.0 units, 95% CI 11.3 to 16.7) were observed immediately following PR. In patients with complete follow-up (n ¼ 37), these improvements remained significantly higher than baseline at 12 months (20.5 m, 95% CI 1.4 to 39.5 for 6MWD; 12.1 points, 95% CI 5.7 to 18.4 for CRQ total score). The time trend and changes in the 6MWD and CRQ scores were not significantly different between the bronchiectasis and the COPD groups (all p > 0.05). This study supports the inclusion of patients with bronchiectasis in existing PR programs. Further prospective RCTs are warranted to substantiate these findings.
Introduction
Bronchiectasis unrelated to cystic fibrosis is a chronic pulmonary condition characterized by persistent cough with purulent sputum, recurrent pulmonary infections and dyspnoea. 1 There is increasing awareness that patients with bronchiectasis experience reduction in both exercise capacity and healthrelated quality of life (HRQoL). [2] [3] [4] One strategy that may improve these deficits is pulmonary rehabilitation (PR), an approach advocated by international PR guidelines. 5, 6 The rationale for recommending PR to patients with bronchiectasis relies primarily on physiological reasoning and the similar clinical profile between this disease and COPD, as characterized by airflow obstruction, frequent infective exacerbation, dyspnoea, fatigue and consequent decrease in exercise tolerance. 2, 5, 6 Although the status of muscular dysfunction in bronchiectasis is yet to be established, this may be due to the chronic systemic inflammatory response and disuse deconditioning. 1, 4 Currently, four primary studies report on outcomes of PR in bronchiectasis. [8] [9] [10] [11] These studies have demonstrated improvement in exercise tolerance following PR but the effect on HRQoL was inconsistent. All four studies have small sample sizes and included only short-term follow-up. One was a randomized controlled trial but the interpretation of results was limited by a high attrition rate and differences in baseline exercise capacity between groups. 11 In addition, an accurate estimate of the benefits of PR for patients with bronchiectasis is difficult due to the confounding effects of the use of inspiratory muscle training (IMT), an intervention not routinely incorporated in clinical practice. 7 The relative efficacy of PR in bronchiectasis compared to the well-documented benefits in COPD is not well examined. Previous PR studies comparing patients with COPD to non-COPD diagnoses had concluded comparable responses, but these studies were limited by the use of a heterogeneous non-COPD group, in which the number of patients with bronchiectasis was small (n ¼ 7 and 12). 9, 12 Furthermore, assessing the degree of benefit was confounded by the reduced functional exercise capacity in patients with COPD compared to other diagnoses. 9, 12 The primary aim of this study was to examine the effects of an out-patient PR program on the functional exercise capacity and HRQoL in patients with bronchiectasis and to determine the sustainability of these effects over 12 months. The secondary aim was to compare these outcomes with patients with COPD who completed the same PR program. It was hypothesized that PR is associated with significant improvements in exercise capacity and HRQoL in patients with bronchiectasis at program completion, and these improvements are comparable to those demonstrated in COPD, which was arbitrarily defined as a difference within 35 m in the 6MWD and 10 points in the CRQ score. 13, 14 Methods
Study subjects
The study subjects were identified retrospectively from the PR databases (up to November 2008) of two tertiary institutions in Melbourne, Australia, which started data collection in May 2000 and January 2001, respectively. There was no significant change to the program content over the period of data collection. Patients with a primary diagnosis of bronchiectasis and who had baseline assessment for PR prior to November 2008 were included. Patients with concomitant pulmonary diagnoses were also accepted. The pulmonary diagnoses were made based on the information given by the source of referral. For patients who had repeated PR enrolment over the data collection period, only data from the initial attendance were analysed. A matched group of patients with COPD who attended PR within the equivalent time period at the institution which incorporated longterm follow-up were selected for comparison. The matching was performed in the hierarchical order of gender, age (+ 10 years) and baseline 6MWD (+30 m). 13, 15 Those patients with bronchiectasis who could not be matched were excluded from between group analysis. Patients who attended less than 70% of the available sessions were considered PR dropouts. 16 Based on data reported by Foster and Thomas (SD 118m), 9 a sample size of 92 patients with bronchiectasis were required to detect a change of 35 m in 6MWD with 80% power and a significance level of 0.05. This 35-m threshold was considered as the minimal clinically meaningful change established based on a population with COPD. 13 The use of data was approved by the Human Ethics Research Committee of each institution.
PR program
The PR programs from both institutions were similar in their admission criteria, program structure and exercise protocol. Patients were admitted if they had a diagnosis of stable, irreversible lung disease, exertional dyspnoea limiting activities of daily living (ADLs) and absence of significant comorbidities which would interfere with the ability or safety to exercise. The exercise program comprised of 6 to 8 weeks of twice weekly supervised exercise sessions in an outpatient setting. The 60 to 90 minutes of exercise training included 15 minutes each of individualized walking and cycling and strengthening exercises. The treadmill exercise intensity was initially set at 70% of the baseline 6MWT speed and progressed weekly by 0.25 to 0.5 km/hr guided by the modified BORG scores for perceived dyspnoea. [17] [18] [19] The prescription and progression of stationary cycling was based on symptom scores, with patients exercising at an intensity to achieve a score of three to four on the 10-point modified BORG scale of shortness of breath. 20 Lower limb strength training consisted of functional exercises such as step-ups and rising from a stool while upper limb training used free weights. 17, 18 The PR program included an hour of structured, group education session delivered after the exercise session, on various topics related to pulmonary disease. 5 The education program included a session on airway clearance techniques, but the overall program was not modified from that provided to patients with the COPD. All patients were given a home exercise program recommending walking two to three times per week at beginning of PR program and were strongly encouraged to continue with their home exercise program.
Outcome measures
The outcome measures were the 6MWD and the CRQ. These were assessed prior to program commencement and at completion. Further assessments at 3, 5 and 12 months after PR were performed at one institution. Although neither instrument has been validated for use specifically in patients with bronchiectasis, they have been used in studies of this population 7, 9, 10, 21 and are widely applied in PR programs. 5, 6, 18 The 6MWT was conducted according to standardized guidelines. 22 A minimum of two tests were performed at baseline assessment and the best distance recorded. Respiratory specific HRQoL was evaluated by the CRQ which includes dyspnoea (up to 5 items), fatigue (4 items), emotional function (7 items) and mastery domains (4 items). The self-administered version of the CRQ with individualized dyspnoea domain was used. 23 A higher score on the CRQ indicates improvement in HRQoL. In determining the proportion of patients achieving clinically meaningful changes, the minimal important change of 35 m for the 6MWT 13 and the minimal important difference (MID) of 0.5 points per CRQ item and a total of 10 points for the total CRQ score, 14 both derived from patients with COPD, was used because the threshold value in bronchiectasis is yet to be established.
Statistical analyses
Statistical analyses were performed using the Statistical Package for Social Sciences (version 16.0). As the bronchiectasis group includes patients with other secondary pulmonary diagnoses, a subgroup analysis comparing those with bronchiectasis alone to those with secondary pulmonary diagnoses was conducted to examine for significant bias between the groups at baseline, as well as the response to PR in terms of 6MWD and CRQ outcomes. The 6MWD and CRQ outcomes were summarized as exact changes from baseline and the corresponding 95% CI. The percentage of patients who achieved clinically meaningful changes for each outcome measure was calculated. Changes at PR completion for the combined patients with bronchiectasis were assessed using paired t tests. The longitudinal changes in patients with complete follow-up were analysed using repeated measures analysis of variance (ANOVA). The differences between bronchiectasis and COPD groups were analysed using repeated measures ANOVA. Due to the interaction of baseline FEV 1 % predicted with diagnosis, baseline FEV 1 % predicted was included as a covariate in the between group analyses. Alpha was set at 0.05 for all analyses.
Results

Patient characteristics
The bronchiectasis group consisted of a total of 111 patients; 72 (65%) patients were from the institution with repeated follow-up (from May 2000 to November 2008) and 39 (35%) patients were from a second institution (from January 2002 to November 2008). Eighty-one (73%) had a diagnosis of bronchiectasis alone and the remaining had additional pulmonary diagnoses of COPD (17%), asthma (4%) and interstitial lung disease (6%). None of the patients repeated the PR in the subsequent year. In comparison to the subgroup of patients with bronchiectasis alone, patients with concomitant pulmonary diagnoses had poorer lung function (FEV 1 % predicted) and worse CRQ-dyspnoea scores at baseline (p ¼ 0.038 and 0.026, respectively). There was also a significantly higher percentage of smokers in the subgroup with secondary pulmonary diagnoses (67%) compared to those with only bronchiectasis (25%; p < 0.001). The group demographics are outlined in Table 1 . There were a total of 15 (14%) PR drop-outs who attended less than 70% of the available PR sessions, but the causes of attrition were not identifiable from the database. No patients were excluded from analysis based on PR attendance rate as all patients with follow-up data attended more than 70% of the sessions and none of the drop-outs returned for follow-up assessment.
The COPD group was selected from a pool of 694 patients from one institution with follow-up for comparison between bronchiectasis and COPD. Out of the 72 patients with bronchiectasis, three could not be matched using the preset criteria because of young age (one patient) and high baseline 6MWD
(two patients). The matching was successful in creating groups that were similar with regards to all baseline parameters except smoking status (p < 0.001) and FEV 1 % predicted (p ¼ 0.006; Table 1 ).
PR in bronchiectasis
Of the initial 111 patients, 95 (86%) returned for assessment at PR completion. Significant improvements were seen in both the 6MWD and CRQ scores at program completion (Table 2, all p < 0.001). Clinically important improvement in the 6MWD and CRQ total score were achieved by 67 (71%) and 55 (60%) patients, respectively. Regarding the CRQ domain scores, 61 (66%), 66 (73%), 39 (43%) and 47 (52%) patients achieved changes greater than the established MID in the dyspnoea, fatigue, emotion and mastery domain, respectively.
There were no significant difference in the changes in 6MWD (p ¼ 0.270) and CRQ score (p ¼ 0.462) at program completion between the subgroup with bronchiectasis alone and the subgroup with concomitant pulmonary diagnoses. The mean change in 6MWD was 50.4 m (95% CI 40.9 to 60.0) for the group with bronchiectasis alone and 60.8 m (95% CI 43.0 to 78.6) for the subgroup with mixed pulmonary diagnoses. The mean change in the CRQ total score for the group with bronchiectasis alone versus the mixed group was 13.4 points (95% CI 10.1 to 16.6) and 15.6 points (95% CI 10.5 to 20.6), respectively. Complete 12 months follow-up data in 6MWD and CRQ was available in 35 (49%) and 37 (51%) patients who attended the PR in the institution with long-term follow-up. The 6MWD at each follow-up is presented in Figure 1 , in which a declining trend between 6 and 12 month follow-up could be observed. However, the decline did not reach significance (p ¼ 0.104) and the 6MWD at 12 months remained significantly higher than baseline (mean difference 20.5 m, 95% CI 1.4 to 39.5, p ¼ 0.036).
In contrast to the deteriorating trend in 6MWD, the original gain in the CRQ total score remained stable for 12 months (p ¼ 0.513; Figure 2 ). Similar trends were observed in the individual domains (all p > 0.05, Figure 3 ). The dyspnoea domain was most responsive to PR with improvements well above the MID (>2.5 points). The mean changes in the fatigue and mastery domain score were also above the MID (>2 points each). In contrast, the mean change in emotional function domain fell below the MID (3.5 points).
Comparison between patients with bronchiectasis and COPD
The changes in exercise capacity and HRQoL of both groups over the 12-month follow-up period are presented in Figures 1 and 2, respectively. There were no significant differences between the two pulmonary diagnosis groups with regards to 6MWD (p ¼ 0.205) and CRQ total score (p ¼ 0.713). The between group difference in 6MWD was 17.5 m (95% CI À6.7 to 41.7) at PR completion and 16.1 m (95% CI -15.0 to 47.1) at the 12-month follow-up. Concerning the CRQ outcome, the between-group difference in the CRQ total score was 3.4 points (95% CI À2.5 to 9.3) at PR completion and -1.3 points (95% CI À10.1 to 8.3) at the 12-month follow-up. There was also no interaction between the time and diagnosis factor for either outcome (p ¼ 0.649 for the 6MWD and p ¼ 0.096 for the CRQ total score). The results in 6MWD and CRQ were not influenced by including baseline FEV 1 % predicted as a covariate (p > 0.05).
Discussion
The present study has demonstrated that patients with bronchiectasis achieve improvements in exercise capacity and HRQoL following attendance at a 6-to 8-week out-patient PR program. Furthermore, these benefits are maintained for up to 12 months post PR completion. This study also confirms that the 12-month outcomes of PR with regards to the 6MWD and CRQ in a small group of patients with bronchiectasis are comparable to those with COPD who completed the same program. The present findings in functional exercise capacity cannot be directly compared with earlier studies because of differences in outcome measures. However, when benefits in exercise capacity were expressed as percentage of change from baseline, the 113% improvement at PR completion of the present study is in keeping with the 118% improvement previously reported in studies that evaluated exercise tolerance using the incremental shuttle walk test. 8, 11 This comparison is justified by the strong association between 6MWD and the incremental shuttle walk distance (r ¼ 0.91) previously observed. 24 Prominent improvement is observed in the dyspnoea and fatigue domains of the CRQ at program completion, with the lower 95% CI of the change score exceeding the MID. This suggests that a PR program designed for a population with COPD is effective in alleviating two of the prominent signs of bronchiectasis -dyspnoea and fatigue. 1 The present result in the disease-specific HRQoL measure is contrary to earlier studies which demonstrated no improvement in SGRQ total score in bronchiectasis groups that received only PR. 8, 11 Such variations may be attributed to differences in disease severity, sample size and assessment tools between the current study and those previously reported. The disease severity of the current bronchiectatic cohort has similar FEV 1 % predicted values (62.8%) to the sample in Newall et al. 11 (61.7%), but differs from the Newall cohort in that 25% of our cohort had concomitant COPD, asthma or interstitial lung disease. These patients were excluded in the study by Newall and colleagues. Although the influence of concomitant pulmonary diagnosis on PR outcome has not been formally examined, observational studies have shown that patients with both bronchiectasis and COPD had more severe pulmonary exacerbations, more bacterial colonization in lower airways and increased hospitalisation than patients having COPD alone. 25, 26 This may account for a greater impairment or severity of dyspnoea prior to undertaking PR, thereby providing a greater scope for improvement.
The previous studies may also have been underpowered due to their small sample number (n < 32). 8, 10, 11 In contrast, the present study is sufficiently powered as it included 95 patients and an exploratory sample calculation using the present data shows that 65 patients were needed to detect a 10-point difference in the CRQ total score. The difference in HRQoL outcome might also be attributed to the enhanced sensitivity of the CRQ compared to the SGRQ to detect changes in HRQoL, which has been reported in COPD studies. 27, 28 This should be confirmed with a larger prospective study.
As the first study to report longitudinal outcomes of PR in patients with bronchiectasis, it is encouraging to observe that despite the absence of a structured maintenance program, the 6MWD remained significantly higher than baseline at 12 months and the CRQ scores similarly remained stable for 12 months in the small group of patients available for long-term follow-up. The observation that the 6MWD at 12 months fell below the clinically meaningful threshold of 35 m may suggest the need of a maintenance program in patients with bronchiectasis. Further prospective controlled studies are therefore needed to establish if clinically meaningful change can be sustained in the long term.
The finding of a partially sustained 6MWD is inconsistent with a previous report which demonstrated a significant decline in incremental shuttle walk distance at 3 months follow-up in the group that received 8 weeks of out-patient PR and placebo IMT training. 11 One potential explanation is that the current study excluded a large number of follow-up incompleters (51%) from analyses, in comparison to the 17% drop-out rate in the previous report. 11 The ceiling effect of the 6MWT in patients with higher mobility function may also contribute to the apparent stability of 6MWD. 29 Such maintenance in exercise capacity after the initial physical training possibly implies that changes other than physiological adaptation may have taken place, these may include changes in lifestyle or improved self-management as observed in COPD populations. 5, 6 The observed improvement in the mastery domain of the CRQ supports this hypothesis. The maintenance of exercise capacity may also be attributed to the ongoing commitment to home exercise although no formal assessment of compliance with the home-based exercise program was undertaken. Therefore, future study on the long-term outcome of PR should monitor adherence to home exercise programs.
This study is also the first in comparing the outcomes of PR in patients with bronchiectasis to patients with COPD. In order to create comparable groups at baseline, care was taken that the COPD comparison group was similar to the bronchiectasis group with regard to factors that are known to affect 6MWD. The similarities in baseline CRQ scores demonstrate that the preset criteria were appropriate.
The present study supports the hypothesis that patients with bronchiectasis do not have a significantly different response to PR than patients with COPD with regards to outcomes in the 6MWD and CRQ. It should however be highlighted that lack of significant difference does not necessarily imply equivalence in outcome. In the present study, equivalence in 6MWD outcome between the groups could not be confirmed because the upper 95%CI for the differences in 6MWD exceeds the þ35 m equivalence threshold, as well as a more recently defined MID of 25 m. 30 This suggests that a larger study is needed to reach a clear conclusion. In contrast, the CRQ data is less ambiguous. As the entire range of the 95%CI for the observed effect lies within the equivalence threshold of þ10 points, there is good evidence that PR results in similar HRQoL outcomes between patients with COPD and patients with bronchiectasis at both program completion and 12 months follow-up.
One unexpected observation is that the COPD group appears to achieve smaller gains in functional exercise capacity than the literature would suggest. 31 This may be the consequence of the matching process, which has resulted in a COPD cohort that has more well-preserved lung function and is less impaired with regard to the 6MWD than typical patients included in COPD studies. 31 Predictor studies have shown that more physically impaired patients achieve greater benefits from PR. [32] [33] [34] Another plausible explanation lies in the exclusion of a large number of participants with incomplete data.
Despite reporting original findings that bear potential clinical significance, this study has several limitations. Firstly, the retrospective design limits the validity of the observed outcomes. The absence of a control group, the lack of control for and assessment of concurrent aetiological conditions, comorbidities and co-interventions means that the absolute benefit of PR is uncertain. Our definition of bronchiectasis and COPD may have introduced grouping error because the diagnostic criteria applied by the referring physician or physiotherapist were unknown. Although both the 6MWD and CRQ appear to improve with PR, their validity in patients with bronchiectasis is yet to be established. Caution should be exercised when applying the present finding to patients who have characteristics differing from the study cohort. A potential weakness of the comparison between patients with COPD and bronchiectasis is the possibility of a type II error as complete data were available in less than half of the patients and the cause of attrition was unidentifiable. Given these limitations, future RCTs using blinded outcome assessors are warranted.
In conclusion, this retrospective review of clinical PR services demonstrated beneficial effects in patients with bronchiectasis who completed an out-patient PR program, in which the principles of exercise prescription and education were derived from recommendations for patients with COPD. These effects remained higher than baseline at 12 months and were not significantly different from those with COPD.
